Osteoarthritis, RA, Gout Exam- Solved
ADEs of colchicine include - ANSWER-N/V/D
Abdominal pain
Hemorrhagic gastropathy
Although Hydroxychloroquine is not fully understood, it can be used as - ANSWER-
Antimalarial drug
- increases lysosomal pH in antigen presenting cells
Anti-inflammatory properties:
- inhibits macrophage proliferation, chemotaxis, lysosomal enzyme release
APAP is effective for - ANSWER-pain relief, not for inflammation
- has weak anti-inflammatory properties
APAP is very well tolerated at recommended therapeutic doses.
What are ADEs associated with it? - ANSWER-BBW:
- Risk of medication errors
- Hepatotoxicity
Common:
- Skin : rash, allergies
- GI issues: N/V/C
Biologic DMARDs are made of large proteins/antibodies (not small molecules)
They target specific inflammatory signals such as: - ANSWER-TNF-α inhibitors → 5
agents
IL-1 blocker → 1 agent
IL-6 blockers → 2 agents
T-cell co-stimulation blocker → 1 agent
B-cell blocker → 1 agent
Biologic DMARDs are not given orally, instead given - ANSWER-parenterally
- IV or subQ
, Colchicine is effective in 2/3 of patients if - ANSWER-given within 24 hours from onset
Common ADEs of NSAIDs include - ANSWER-Nausea, dyspepsia
Increased bruising or bleeding
CNS effects:
- dizziness
- depression
Tinnitus
Compare and contrast APAP vs NSAIDs for the following
1. GI effects:
2. Platelets / bleeding:
3. Renal / uric acid:
4. Respiratory / cardiovascular - ANSWER-1. GI effects:
- APAP → no GI irritation, erosion, or bleeding
- NSAIDs → risk of GI ulceration and bleeding
2. Platelets / bleeding:
- APAP → no effect on platelet aggregation or bleeding time
- NSAIDs/salicylates → can impair platelet function
3. Renal / uric acid:
- APAP → does not alter uric acid excretion
- NSAIDs → may affect renal function
4. Respiratory / cardiovascular
- APAP → no direct respiratory stimulation or CV dilation
- Salicylates → can cause respiratory alkalosis followed by renal compensation; toxic
doses → metabolic acidosis
Describe APAP hepatotoxicity.
Who are the "at-risk" populations? - ANSWER-Toxic doses (adults):
Single dose:
10-15 g → hepatotoxicity
20 g → potential fatal liver damage
At-risk populations:
- Chronic alcohol users or significant ethanol intake
- leads to toxic effects at lower doses, even at therapeutic levels
Always warn patients about alcohol consumption (max daily dose 4g)
ADEs of colchicine include - ANSWER-N/V/D
Abdominal pain
Hemorrhagic gastropathy
Although Hydroxychloroquine is not fully understood, it can be used as - ANSWER-
Antimalarial drug
- increases lysosomal pH in antigen presenting cells
Anti-inflammatory properties:
- inhibits macrophage proliferation, chemotaxis, lysosomal enzyme release
APAP is effective for - ANSWER-pain relief, not for inflammation
- has weak anti-inflammatory properties
APAP is very well tolerated at recommended therapeutic doses.
What are ADEs associated with it? - ANSWER-BBW:
- Risk of medication errors
- Hepatotoxicity
Common:
- Skin : rash, allergies
- GI issues: N/V/C
Biologic DMARDs are made of large proteins/antibodies (not small molecules)
They target specific inflammatory signals such as: - ANSWER-TNF-α inhibitors → 5
agents
IL-1 blocker → 1 agent
IL-6 blockers → 2 agents
T-cell co-stimulation blocker → 1 agent
B-cell blocker → 1 agent
Biologic DMARDs are not given orally, instead given - ANSWER-parenterally
- IV or subQ
, Colchicine is effective in 2/3 of patients if - ANSWER-given within 24 hours from onset
Common ADEs of NSAIDs include - ANSWER-Nausea, dyspepsia
Increased bruising or bleeding
CNS effects:
- dizziness
- depression
Tinnitus
Compare and contrast APAP vs NSAIDs for the following
1. GI effects:
2. Platelets / bleeding:
3. Renal / uric acid:
4. Respiratory / cardiovascular - ANSWER-1. GI effects:
- APAP → no GI irritation, erosion, or bleeding
- NSAIDs → risk of GI ulceration and bleeding
2. Platelets / bleeding:
- APAP → no effect on platelet aggregation or bleeding time
- NSAIDs/salicylates → can impair platelet function
3. Renal / uric acid:
- APAP → does not alter uric acid excretion
- NSAIDs → may affect renal function
4. Respiratory / cardiovascular
- APAP → no direct respiratory stimulation or CV dilation
- Salicylates → can cause respiratory alkalosis followed by renal compensation; toxic
doses → metabolic acidosis
Describe APAP hepatotoxicity.
Who are the "at-risk" populations? - ANSWER-Toxic doses (adults):
Single dose:
10-15 g → hepatotoxicity
20 g → potential fatal liver damage
At-risk populations:
- Chronic alcohol users or significant ethanol intake
- leads to toxic effects at lower doses, even at therapeutic levels
Always warn patients about alcohol consumption (max daily dose 4g)
